Insmed Inc will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the Pulmonary Vascular Research Institute (PVRI) 2026 congress in Dublin from January 28 to February 1, 2026.

TPIP is a dry powder formulation of treprostinil palmitil, being evaluated as a once-daily therapy for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders. TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction. 

Presentations will feature the Phase 3 PALM-PAH study design and an encore presentation of the topline results from the Phase 2b study of TPIP in pulmonary arterial hypertension (PAH). Additionally, a new Functional Respiratory Imaging analysis from the Phase 2b PAH study, as well as data evaluating the pulmonary vasodilatory effect of TPIP in rat models will be presented.

The Phase 2b study of TPIP in patients with PAH was a randomized, double-blind, multicenter, placebo-controlled study designed to evaluate the efficacy, safety, and pharmacokinetics of TPIP, administered once daily, in patients diagnosed with PAH (World Health Organization Group 1). The study was conducted at 44 sites and enrolled 102 adult participants. Patients started at a dose of 80 µg once daily (TPIP or matching placebo) and were titrated up to their maximum tolerated dose, or to the maximum allowable dose of 640 µg, once daily over a three-week period, with the possibility of a final dose increase occurring at Week 5. Patients self-administered TPIP or placebo using a capsule-based inhalation device. The primary endpoint was change from baseline in pulmonary vascular resistance (PVR) versus placebo at Week 16. Secondary endpoints were six-minute walk distance (6MWD), N-terminal pro b-type natriuretic peptide (NT-proBNP) concentrations, pharmacokinetics, and safety/tolerability. Patients who completed the study could enroll in a long-term open-label extension, with the option to titrate up to a maximum tolerated dose of 1,280 µg once daily. 

“We are pleased that TPIP will have a significant presence at this year’s PVRI 2026 congress, reflecting the growing body of evidence supporting its potential to become the prostanoid of choice,” said Martina Flammer, M.D., MBA, Chief Medical Officer, Insmed. “Collectively, these Phase 2b clinical, advanced imaging, and translational preclinical data provide a strong foundation as we initiate multiple Phase 3 programs, including the PALM-PAH study, with the goal of improving outcomes for patients.”

Presentations:

  • Presentation Details, Moderated Poster Discussion – Robinson, Friday, January 30, 2026, 15:10 – 16:15, Robinson Suite, Poster Board: 41
    • Lead Author and Presenter: Tam Nguyen
    • Title: Pulmonary Vasodilation with TPIP in Rat Isolated Perfused Lungs
  • Presentation Details, Moderated Poster Discussion – Higgins, Saturday, January 31, 2026, 09:55 – 11:00, Higgins Suite, Poster Board: 7
    • Lead Author: Ekkehard Grünig, Presenter: Raymond Benza
    • Title: Study Design of a Phase 3 Trial of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Arterial Hypertension (PAH)
  • Presentation Details, Moderated Poster Discussion – Higgins, Saturday, Jan 31, 2026, 09:55 – 11:00, Higgins Suite, Poster Board: 8
    • Lead Author and Presenter: Ioana Preston
    • Title: Novel Insights from Functional Respiratory Imaging (FRI) Analysis in a Phase 2 Randomized, Double-blind, Placebo-controlled Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension (PAH)
  • Presentation Details, Moderated Poster Discussion – Higgins, Saturday, Jan 31, 2026, 09:55 – 11:00, Higgins Suite, Poster Board: 6
    • Lead Author: Ekkehard Grünig, Presenter: Amy Boutet
    • Title: Encore Presentation: A Randomized, Double-blind, Placebo-controlled Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients (pts) with Pulmonary Arterial Hypertension (PAH)